TABLE 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Placebo group | | Troglitazone group | | *P* |
| *n* | 122 | | 114 | |  |
| Clinical characteristics |  | |  | |  |
| Age (years) | 34.3 | ± 6.5 | 34.9 | ± 6.6 | 0.52 |
| BMI (kg/m2) | 30.3 | ± 5.3 | 30.6 | ± 6.1 | 0.63 |
| Waist-to-hip circumference ratio | 0.86 | ± 0.05 | 0.85 | ± 0.06 | 0.19 |
| Using hormonal contraceptives\* | 48% | | 43% | | 0.41 |
| OGTT† |  | |  | |  |
| Fasting glucose (mg/dl) | 98.1 | ± 9.1 | 98.7 | ± 10.2 | 0.64 |
| 2-h glucose | 154.0 | ± 24.0 | 154.4 | ± 27.0 | 0.97 |
| Total glucose area (mg/dl × min × 10-3) ‡ | 18.7 | ± 2.0 | 189 | ± 2.0 | 0.25 |
| Impaired glucose tolerance | 72% | | 69% | | 0.66 |
| Fasting insulin (µU/ml) | 16 | ± 7.5 | 17.0 | ± 10.8 | 0.82 |
| Total insulin area (µU/ml × min) ‡ | 10,209 | ± 5536 | 9,902 | ± 6543 | 0.55 |